Journal
STEM CELL REPORTS
Volume 11, Issue 1, Pages 242-257Publisher
CELL PRESS
DOI: 10.1016/j.stemcr.2018.06.001
Keywords
-
Categories
Funding
- Fondation Leducq
- NIH [T32HL007824, R01HL130423, R01HL125863]
- American Heart Association [14SFRN20490315, 14SFRN20840000]
- AstraZeneca
Ask authors/readers for more resources
Mesenchymal stem cells (MSCs) reportedly exist in a vascular niche occupying the outer adventitial layer. However, these cells have not been well characterized in vivo in medium- and large-sized arteries in humans, and their potential pathological role is unknown. To address this, healthy and diseased arterial tissues were obtained as surplus surgical specimens and freshly processed. We identified that CD90 marks a rare adventitial population that co-expresses MSC markers including PDGFR alpha, CD44, CD73, and CD105. However, unlike CD90, these additional markers were widely expressed by other cells. Human adventitial CD90+ cells fulfilled standard MSC criteria, including plastic adherence, spindle morphology, passage ability, colony formation, and differentiation into adipocytes, osteo-blasts, and chondrocytes. Phenotypic and transcriptomic profiling, as well as adoptive transfer experiments, revealed a potential role in vascular disease pathogenesis, with the transcriptomic disease signature of these cells being represented in an aortic regulatory gene network that is operative in atherosclerosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available